Effect of Iron Therapy as an Adjunct to Epoetin Alfa in the Anemia of Cancer Chemotherapy

• Status: Completed
• Trial end date: 2003-12-01
• Target enrollment: 0
• Participant gender: All

Summary

This study evaluates the safety and efficacy of Ferrlecit® (ferric gluconate; a form of intravenous iron) or ferrous sulfate (a form of oral iron) in improving the response to epoetin alfa among anemic cancer patients receiving chemotherapy.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Watson Pharmaceuticals
• Treatments: Epoetin Alfa; Ferric Compounds; Ferric gluconate; Iron

Criteria

Inclusion Criteria:

• Diagnosis of nonmyeloid malignancy

• Moderate to severe anemia

• Adequate iron stores as measured by either TSAT or ferritin

• About to start cycle of chemotherapy

• Eligible for epoetin alfa therapy

Exclusion Criteria:

• Highly elevated TSAT or ferritin

• Recent transfusion, epoetin alfa, darbepoetin or intravenous iron

• Medical conditions that would confound the efficacy evaluation